Soleno Therapeutics, Inc. (NASDAQ:SLNO) Shares Acquired by Deutsche Bank AG

Deutsche Bank AG raised its stake in Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) by 44.8% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 119,455 shares of the company's stock after purchasing an additional 36,971 shares during the period. Deutsche Bank AG owned 0.28% of Soleno Therapeutics worth $5,370,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Nantahala Capital Management LLC grew its position in shares of Soleno Therapeutics by 20.1% during the 4th quarter. Nantahala Capital Management LLC now owns 3,928,966 shares of the company's stock valued at $176,607,000 after buying an additional 658,518 shares during the last quarter. Avoro Capital Advisors LLC grew its position in shares of Soleno Therapeutics by 15.8% during the 4th quarter. Avoro Capital Advisors LLC now owns 2,525,000 shares of the company's stock valued at $113,499,000 after buying an additional 344,000 shares during the last quarter. TimesSquare Capital Management LLC bought a new stake in shares of Soleno Therapeutics during the 4th quarter valued at about $15,273,000. Price T Rowe Associates Inc. MD grew its position in shares of Soleno Therapeutics by 24.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,630,718 shares of the company's stock valued at $73,301,000 after buying an additional 321,223 shares during the last quarter. Finally, Vanguard Group Inc. grew its position in shares of Soleno Therapeutics by 19.2% during the 4th quarter. Vanguard Group Inc. now owns 1,884,533 shares of the company's stock valued at $84,710,000 after buying an additional 303,806 shares during the last quarter. Institutional investors own 97.42% of the company's stock.

Insider Transactions at Soleno Therapeutics

In other news, CEO Bhatnagar Anish sold 699,095 shares of the company's stock in a transaction that occurred on Thursday, March 27th. The shares were sold at an average price of $67.62, for a total value of $47,272,803.90. Following the completion of the sale, the chief executive officer now directly owns 577,076 shares of the company's stock, valued at approximately $39,021,879.12. This represents a 54.78% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Patricia C. Hirano sold 128,653 shares of the company's stock in a transaction that occurred on Thursday, March 27th. The stock was sold at an average price of $68.32, for a total transaction of $8,789,572.96. Following the completion of the sale, the insider now directly owns 55,789 shares of the company's stock, valued at approximately $3,811,504.48. This represents a 69.75% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 942,672 shares of company stock valued at $64,058,781. Company insiders own 12.30% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on SLNO shares. Piper Sandler boosted their price objective on shares of Soleno Therapeutics from $93.00 to $145.00 and gave the company an "overweight" rating in a research report on Thursday, April 24th. UBS Group set a $105.00 price objective on shares of Soleno Therapeutics in a research report on Thursday, March 27th. Guggenheim boosted their price objective on shares of Soleno Therapeutics from $81.00 to $97.00 and gave the company a "buy" rating in a research report on Thursday, May 8th. Stifel Nicolaus boosted their target price on shares of Soleno Therapeutics from $74.00 to $108.00 and gave the company a "buy" rating in a research note on Friday, March 28th. Finally, HC Wainwright restated a "buy" rating and issued a $100.00 target price on shares of Soleno Therapeutics in a research report on Tuesday, April 15th. Eight analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $106.78.

Soleno Therapeutics Stock Up 0.8%

NASDAQ SLNO traded up $0.59 on Thursday, hitting $73.89. The stock had a trading volume of 588,527 shares, compared to its average volume of 746,036. Soleno Therapeutics, Inc. has a one year low of $36.93 and a one year high of $80.99. The stock has a market cap of $3.72 billion, a price-to-earnings ratio of -22.26 and a beta of -2.67. The company's 50-day moving average is $67.86 and its two-hundred day moving average is $55.45.

Soleno Therapeutics (NASDAQ:SLNO - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported ($0.95) earnings per share for the quarter, topping analysts' consensus estimates of ($1.14) by $0.19. On average, sell-side analysts anticipate that Soleno Therapeutics, Inc. will post -3.72 earnings per share for the current year.

About Soleno Therapeutics

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.